Gavin MacBeath - 13 Jun 2023 Form 4 Insider Report for TScan Therapeutics, Inc. (TCRX)

Role
Chief Executive Officer, Director
Signature
/s/ Gavin MacBeath
Issuer symbol
TCRX
Transactions as of
13 Jun 2023
Transactions value $
$0
Form type
4
Date filed
15 Jun 2023, 18:08
Previous filing
06 Feb 2023
Next filing
11 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TCRX Stock Option (Right to Buy) Award $0 +1.12M $0.00 1.12M 13 Jun 2023 Voting Common Stock 1.12M $2.49 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 536,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 585,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.